DiaMedica Therapeutics(NASDAQ) DMAC

DiaMedica Therapeutics makes new medicines for people with serious brain and kidney issues. It helps pregnant women with high blood pressure and patients who have had strokes. These treatments work to improve blood flow and protect vital organs.

Healing Hearts and Minds

• DM199 for Preeclampsia: Synthetic protein used to lower blood pressure in pregnant women suffering from high blood pressure while protecting the fetus.
• DM199 for Stroke: Treatment candidate designed to improve blood flow and nerve survival after an acute ischemic stroke; holds FDA Fast Track status.
• DM300: Pre-clinical candidate being studied as a potential treatment for inflammatory diseases such as severe acute pancreatitis.

Steps Toward Global Expansion

• Expanded the ReMEDy2 clinical trial into six European countries to improve patient enrollment and site activation rates.
• Raised $30 million in net proceeds through a private placement of common shares to investors in July 2025.
• Received approval from Health Canada in March 2026 to start a new Phase 2 study for preeclampsia.
• Reported interim results from a South African Phase 2 study in July 2025 showing significant blood pressure reduction.

A Safer Path to Treatment

The company uses recombinant DNA technology to create a synthetic version of a human protein that improves blood flow. This method removes the risk of passing diseases often found in versions taken from animal or human sources.

Recent Financial Performance

• Net loss reached $10.0 million in Q1 2026, worsening 30.3% from the $7.7 million loss in Q1 2025.
• Operating cash flow worsened to negative $9.1 million in Q1 2026, a 27.0% decline from the previous year.
• Research and development spending rose to $8.0 million in Q1 2026, up from $5.7 million in Q1 2025.
• Total cash and marketable securities were $51.3 million as of March 31, 2026.
• Market capitalization increased to $364.2 million in Q1 2026, up 124.3% year-over-year.

The Path Ahead

DiaMedica has transitioned into a late-stage clinical company focused on high-need vascular and kidney diseases. Its focus on synthetic protein technology aims to provide safer alternatives to existing animal-derived treatments used in Asia.